Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Blocking the interactions between bromodomain and extraterminal (BET) proteins and acetylated lysines of histones by small molecules has important implications for the treatment of cancers and other diseases. Many pan-BET inhibitors have shown satisfactory results in clinical trials, but their potential for poor tolerability and toxicity persist. However, recently reported studies illustrate that some BET bromodomain (BET-BD1 or BET-BD2)-selective inhibitors have advantage over pan-inhibitors, including reduced toxicity concerns. Furthermore, some selective BET inhibitors have similar or even better therapeutic efficacy in inflammatory diseases or cancers. Therefore, the development of selective BET inhibitors has become a hot spot for medicinal chemists. Here, we summarize the known selective BET-BD1 and BET-BD2 inhibitors and review the methods for enhancing the selectivity and potency of these inhibitors based on their different modes of interactions with BET-BD1 or BET-BD2. Finally, we discuss prospective strategies that selectively target the bromodomains of BET proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors are capable of specifically targeting categories, subtypes, and structural domains,491 potentially providing more pronounced benefits in terms of efficacy, safety, and tolerability.67”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [67]
Citations
Cites
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
BRD4 and Cancer: going beyond transcriptional regulation
Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 708
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation
Wu, S.-Y., & Chiang, C.-M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700001200 · Cited by 679
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N. R., Lam, E. Y. N., Chung, C.-W., Bamborough, P., Petretich, M., et al. (2020) · Science · doi:10.1126/science.aaz8455 · Cited by 422
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Faivre, E. J., McDaniel, K. F., Albert, D. H., Mantena, S. R., Plotnik, J. P., Wilcox, D., Zhang, L., Bui, M. H., Sheppard, G. S., Wang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-1930-8 · Cited by 408
BET inhibitors: a novel epigenetic approach
Doroshow, D. B., Eder, J. P., & LoRusso, P. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx157 · Cited by 367
Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
Wu, S.-Y., Lee, A.-Y., Lai, H.-T., Zhang, H., & Chiang, C.-M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.006 · Cited by 347
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 305
Drug Discovery Targeting Bromodomain-Containing Protein 4
Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01761 · Cited by 303
Bromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Lewin, J., Soria, J.-C., Stathis, A., Delord, J.-P., Peters, S., Awada, A., Aftimos, P. G., Bekradda, M., Rezai, K., Zeng, Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2292 · Cited by 284
Protein‐Reactive Natural Products
Drahl, C., Cravatt, B. F., & Sorensen, E. J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200500900 · Cited by 250
Clinical trials for BET inhibitors run ahead of the science
Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247
Alqahtani, A., Choucair, K., Ashraf, M., Hammouda, D. M., Alloghbi, A., Khan, T., Senzer, N., & Nemunaitis, J. (2019) · Future Science OA · doi:10.4155/fsoa-2018-0115 · Cited by 240
Lamonica, J. M., Deng, W., Kadauke, S., Campbell, A. E., Gamsjaeger, R., Wang, H., Cheng, Y., Billin, A. N., Hardison, R. C., Mackay, J. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102140108 · Cited by 238
Bromodomains: Structure, function and pharmacology of inhibition
Ferri, E., Petosa, C., & McKenna, C. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.005 · Cited by 229
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Fu, L.-L., Tian, M., Li, X., Li, J.-J., Huang, J., Ouyang, L., Zhang, Y., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3551 · Cited by 221
Self-citationPiha-Paul, S. A., Hann, C. L., French, C. A., Cousin, S., Braña, I., Cassier, P. A., Moreno, V., de Bono, J. S., Harward, S. D., Ferron-Brady, G., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz093 · Cited by 215
Albrecht, B. K., Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Côté, A., Leblanc, Y., Nasveschuk, C. G., Bellon, S., Bergeron, L., Campbell, R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01882 · Cited by 212
Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.041 · Cited by 209
Opposing Functions of BRD4 Isoforms in Breast Cancer
Wu, S.-Y., Lee, C.-F., Lai, H.-T., Yu, C.-T., Lee, J.-E., Zuo, H., Tsai, S. Y., Tsai, M.-J., Ge, K., Wan, Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.034 · Cited by 192
Bolden, J. E., Tasdemir, N., Dow, L. E., van Es, J. H., Wilkinson, J. E., Zhao, Z., Clevers, H., & Lowe, S. W. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.025 · Cited by 185
Targeting Cancer Cells with BET Bromodomain Inhibitors
Xu, Y., & Vakoc, C. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026674 · Cited by 180
Nicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A., Borgman, M., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.015 · Cited by 174
BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., & Callanan, M. B. (2018) · Biomedicines · doi:10.3390/biomedicines6010016 · Cited by 173
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Yin, M., Guo, Y., Hu, R., Cai, W. L., Li, Y., Pei, S., Sun, H., Peng, C., Li, J., Ye, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15290-0 · Cited by 171
Self-citationPiha-Paul, S. A., Sachdev, J. C., Barve, M. A., LoRusso, P. M., Szmulewitz, R. Z., Patel, S. P., Lara, P. N., Chen, X., Hu, B., Freise, K. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0578 · Cited by 166
Ray, K. K., Nicholls, S. J., Buhr, K. A., Ginsberg, H. N., Johansson, J. O., Kalantar-Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N., Sweeney, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3308 · Cited by 166
Targeting Brd4 for cancer therapy: inhibitors and degraders
Duan, Y., Guan, Y., Qin, W., Zhai, X., Yu, B., & Liu, H. (2018) · MedChemComm · doi:10.1039/c8md00198g · Cited by 161
Epigenetic drug discovery: breaking through the immune barrier
Tough, D. F., Tak, P. P., Tarakhovsky, A., & Prinjha, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.185 · Cited by 158
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
Gacias, M., Gerona-Navarro, G., Plotnikov, A. N., Zhang, G., Zeng, L., Kaur, J., Moy, G., Rusinova, E., Rodriguez, Y., Matikainen, B., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.05.009 · Cited by 155
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
Tyler, D. S., Vappiani, J., Cañeque, T., Lam, E. Y. N., Ward, A., Gilan, O., Chan, Y.-C., Hienzsch, A., Rutkowska, A., Werner, T., et al. (2017) · Science · doi:10.1126/science.aal2066 · Cited by 146
Chiang, C.-M. (2009) · F1000 Biology Reports · doi:10.3410/b1-98 · Cited by 143
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Leal, A. S., Williams, C. R., Royce, D. B., Pioli, P. A., Sporn, M. B., & Liby, K. T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.021 · Cited by 142
A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes
Baud, M. G. J., Lin-Shiao, E., Cardote, T., Tallant, C., Pschibul, A., Chan, K.-H., Zengerle, M., Garcia, J. R., Kwan, T. T.-L., Ferguson, F. M., et al. (2014) · Science · doi:10.1126/science.1249830 · Cited by 141
Sun, Y., Han, J., Wang, Z., Li, X., Sun, Y., & Hu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.621093 · Cited by 141
Cheung, K., Lu, G., Sharma, R., Vincek, A. S., Zhang, R., Plotnikov, A. N., Zhang, F., Zhang, Q., Ju, Y., Hu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615601114 · Cited by 139
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138
McDaniel, K. F., Wang, L., Soltwedel, T., Fidanze, S. D., Hasvold, L. A., Liu, D., Mantei, R. A., Pratt, J. K., Sheppard, G. S., Bui, M. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00746 · Cited by 135
Tang, P., Zhang, J., Liu, J., Chiang, C.-M., & Ouyang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01487 · Cited by 135
Self-citationStructure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Zhang, G., Plotnikov, A. N., Rusinova, E., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M., & Zhou, M.-M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401334s · Cited by 132
Sheppard, G. S., Wang, L., Fidanze, S. D., Hasvold, L. A., Liu, D., Pratt, J. K., Park, C. H., Longenecker, K., Qiu, W., Torrent, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00628 · Cited by 127
Tsujikawa, L. M., Fu, L., Das, S., Halliday, C., Rakai, B. D., Stotz, S. C., Sarsons, C. D., Gilham, D., Daze, E., Wasiak, S., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0696-z · Cited by 126
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review
Yang, C.-Y., Qin, C., Bai, L., & Wang, S. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.04.001 · Cited by 121
Self-citationLaw, R. P., Atkinson, S. J., Bamborough, P., Chung, C.-W., Demont, E. H., Gordon, L. J., Lindon, M., Prinjha, R. K., Watson, A. J. B., & Hirst, D. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01666 · Cited by 117
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
Bechter, O., & Schöffski, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107479 · Cited by 108
Ouyang, L., Zhang, L., Liu, J., Fu, L., Yao, D., Zhao, Y., Zhang, S., Wang, G., He, G., & Liu, B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00275 · Cited by 107
Self-citationLiu, Z., Tian, B., Chen, H., Wang, P., Brasier, A. R., & Zhou, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.006 · Cited by 107
Discovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M.-M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 106
Functions of BET proteins in erythroid gene expression
Stonestrom, A. J., Hsu, S. C., Jahn, K. S., Huang, P., Keller, C. A., Giardine, B. M., Kadauke, S., Campbell, A. E., Evans, P., Hardison, R. C., et al. (2015) · Blood · doi:10.1182/blood-2014-10-607309 · Cited by 103
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Morgado‐Pascual, J. L., Rayego‐Mateos, S., Tejedor-Santamaria, L., Suárez-Álvarez, B., & Ruiz‐Ortega, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01315 · Cited by 103
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Kulikowski, E., Rakai, B. D., & Wong, N. C. W. (2021) · Medicinal Research Reviews · doi:10.1002/med.21730 · Cited by 102
Liu, Z., Chen, H., Wang, P., Li, Y., Wold, E. A., Leonard, P. G., Joseph, S., Brasier, A. R., Tian, B., & Zhou, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00035 · Cited by 95
Self-citationThe Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
Zhao, Y., Yang, C.-Y., & Wang, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4014407 · Cited by 94
Self-citationBromodomain Drug Discovery – the Past, the Present, and the Future
Pervaiz, M., Mishra, P., & Günther, S. (2018) · The Chemical Record · doi:10.1002/tcr.201800074 · Cited by 94
Wu, S.-Y., Nin, D. S., Lee, A.-Y., Simanski, S., Kodadek, T. J., & Chiang, C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.001 · Cited by 93
Raux, B., Voitovich, Y. V., Derviaux, C., Lugari, A., Rebuffet, E., Milhas, S., Priet, S., Roux, T., Trinquet, E., Guillemot, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01708 · Cited by 90
Watson, R. J., Bamborough, P., Barnett, H., Chung, C.-W., Davis, R., Gordon, L., Grandi, P., Petretich, M., Phillipou, A., Prinjha, R. K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00614 · Cited by 88
Divakaran, A., Talluri, S., Ayoub, A. M., Mishra, N. K., Cui, H., Widen, J. C., Berndt, N., Zhu, J.-Y., Carlson, A. S., Topczewski, J. J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01248 · Cited by 83
Jiang, F., Hu, Q., Zhang, Z., Li, H., Li, H., Zhang, D., Li, H., Ma, Y., Xu, J., Chen, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01010 · Cited by 83
Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
Liang, D., Yu, Y., & Ma, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112426 · Cited by 73
Targeting BET bromodomain proteins in cancer: The example of lymphomas
Spriano, F., Stathis, A., & Bertoni, F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107631 · Cited by 73
BET Bromodomain Proteins as Cancer Therapeutic Targets
Shu, S., & Polyak, K. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030908 · Cited by 72
Liu, Z., Li, Y., Chen, H., Lai, H., Wang, P., Wu, S., Wold, E. A., Leonard, P. G., Joseph, S., Hu, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01851 · Cited by 72
Self-citationDomain-selective targeting of BET proteins in cancer and immunological diseases
Petretich, M., Demont, E. H., & Grandi, P. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.003 · Cited by 69
Seal, J. T., Atkinson, S. J., Aylott, H., Bamborough, P., Chung, C.-W., Copley, R. C. B., Gordon, L., Grandi, P., Gray, J. R. J., Harrison, L. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00796 · Cited by 68
Chen, D., Lu, T., Yan, Z., Lu, W., Zhou, F., Lyu, X., Xu, B., Jiang, H., Chen, K., Luo, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111633 · Cited by 67
Identification of Covalent Bromodomain Binders through DNA Display of Small Molecules
Daguer, J., Zambaldo, C., Abegg, D., Barluenga, S., Tallant, C., Müller, S., Adibekian, A., & Winssinger, N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412276 · Cited by 65
Apabetalone downregulates factors and pathways associated with vascular calcification
Gilham, D., Tsujikawa, L. M., Sarsons, C. D., Halliday, C., Wasiak, S., Stotz, S. C., Jahagirdar, R., Sweeney, M., Johansson, J. O., Wong, N. C. W., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.002 · Cited by 65
Abramson, J. S., Blum, K. A., Flinn, I. W., Gutierrez, M., Goy, A., Maris, M., Cooper, M., O'Meara, M., Borger, D., Mertz, J., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1491.1491 · Cited by 62
RVX-297- a novel BD2 selective inhibitor of BET bromodomains
Kharenko, O. A., Gesner, E. M., Patel, R. G., Norek, K., White, A., Fontano, E., Suto, R. K., Young, P. R., McLure, K. G., & Hansen, H. C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.021 · Cited by 61
Galdeano, C., & Ciulli, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0059 · Cited by 59
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors
Ramadoss, M., & Mahadevan, V. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.011 · Cited by 59
BRD4 inhibition for the treatment of pathological organ fibrosis
Stratton, M. S., Haldar, S. M., & McKinsey, T. A. (2017) · F1000Research · doi:10.12688/f1000research.11339.1 · Cited by 58
Jahagirdar, R., Attwell, S., Marusic, S., Bendele, A., Shenoy, N., McLure, K. G., Gilham, D., Norek, K., Hansen, H. C., Yu, R., et al. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.110379 · Cited by 58
Phospho-BRD4: transcription plasticity and drug targeting
Chiang, C. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.05.003 · Cited by 57
Preston, A., Atkinson, S., Bamborough, P., Chung, C.-W., Craggs, P. D., Gordon, L., Grandi, P., Gray, J. R. J., Jones, E. J., Lindon, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00605 · Cited by 57
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
Chen, J., Li, Y., Zhang, J., Zhang, M., Wei, A., Liu, H., Xie, Z., Ren, W., Duan, W., Zhang, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112868 · Cited by 56
Self-citationRianjongdee, F., Atkinson, S. J., Chung, C., Grandi, P., Gray, J. R., Kaushansky, L. J., Medeiros, P., Messenger, C., Phillipou, A., Preston, A. G. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00412 · Cited by 53
Kharenko, O. A., Patel, R. G., Brown, S. D., Calosing, C., White, A., Lakshminarasimhan, D., Suto, R. K., Duffy, B. C., Kitchen, D. B., McLure, K. G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00666 · Cited by 52
Reyes-Garau, D., Ribeiro, M. L., & Roué, G. (2019) · Cancers · doi:10.3390/cancers11101483 · Cited by 50
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
Slavish, P. J., Chi, L., Yun, M., Tsurkan, L. G., Martinez, N. E., Jonchère, B., Chai, S. C., Connelly, M., Waddell, M. B., Das, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3934 · Cited by 49
Wellaway, C. R., Bamborough, P., Bernard, S. G., Chung, C.-W., Craggs, P. D., Cutler, L., Demont, E. H., Evans, J. P., Gordon, L., Karamshi, B., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00566 · Cited by 49
Jiang, F., Wei, Q., Li, H., Li, H., Cui, Y., Ma, Y., Chen, H., Cao, P., Lu, T., & Chen, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115181 · Cited by 48
Olp, M. D., Sprague, D. J., Goetz, C. J., Kathman, S. G., Wynia‐Smith, S. L., Shishodia, S., Summers, S. B., Xu, Z., Statsyuk, A. V., & Smith, B. C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00058 · Cited by 47
Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition
Runcie, A. C., Zengerle, M., Chan, K.-H., Testa, A., van Beurden, L., Baud, M. G. J., Epemolu, O., Ellis, L. C. J., Read, K. D., Coulthard, V., et al. (2018) · Chemical Science · doi:10.1039/c7sc02536j · Cited by 45
Cui, H., Divakaran, A., Pandey, A. K., Johnson, J. A., Zahid, H., Hoell, Z. J., Ellingson, M. O., Shi, K., Aihara, H., Harki, D. A., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202008625 · Cited by 45
Cui, H., Carlson, A. S., Schleiff, M. A., Divakaran, A., Johnson, J. A., Buchholz, C. R., Zahid, H., Vail, N. R., Shi, K., Aihara, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00933 · Cited by 45
Jones, K. L., Beaumont, D. M., Bernard, S. G., Bit, R. A., Campbell, S. P., Chung, C., Cutler, L., Demont, E. H., Dennis, K., Gordon, L. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00855 · Cited by 44
Braun, T., & Gardin, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1335711 · Cited by 43
The therapeutic potential of BRD4 in cardiovascular disease
Lin, S., & Du, L. (2020) · Hypertension Research · doi:10.1038/s41440-020-0459-4 · Cited by 41
Nonequivalent Response to Bromodomain-Targeting BET Inhibitors in Oligodendrocyte Cell Fate Decision
Chiang, C. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.003 · Cited by 37
Aylott, H. E., Atkinson, S. J., Bamborough, P., Bassil, A. K., Chung, C., Gordon, L. J., Grandi, P., Gray, J. R., Harrison, L. A., Hayhow, T. G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02156 · Cited by 35
Preston, A. G. S., Atkinson, S. J., Bamborough, P., Chung, C., Gordon, L. J., Grandi, P., Gray, J. R., Harrison, L. A., Lewis, A. J., Lugo, D., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00247 · Cited by 34
Li, Z., Xiao, S.-H., Yang, Y., Chen, C., Lu, T., Chen, Z., Jiang, H., Chen, S., Luo, C., & Zhou, B. N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01784 · Cited by 32
Harrison, L. A., Atkinson, S. J., Bassil, A. K., Chung, C., Grandi, P., Gray, J. R., Levernier, E., Lewis, A. J., Lugo, D., Messenger, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02155 · Cited by 31
D’Ascenzio, M., Pugh, K., Konietzny, R., Berridge, G., Tallant, C., Hashem, S., Monteiro, O., Thomas, J. R., Schirle, M., Knapp, S., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807825 · Cited by 30
Rodrı́guez, Y., Gerona‐Navarro, G., Osman, R., & Zhou, M. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25818 · Cited by 30
Seal, J. T., Atkinson, S. J., Bamborough, P., Bassil, A. K., Chung, C., Foley, J. J., Gordon, L. J., Grandi, P., Gray, J. R., Harrison, L. A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00365 · Cited by 29
Lucas, S. C. C., Atkinson, S. J., Chung, C., Davis, R. P., Gordon, L. J., Grandi, P., Gray, J. R., Grimes, T., Phillipou, A. N., Preston, A. G. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00344 · Cited by 28
Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
Shi, J., Song, S., Han, H., Xu, H., Huang, M., Qian, C., Zhang, X., Ouyang, L., Hong, Y., Zhuang, W., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00554 · Cited by 26
Self-citationMa, J., Chen, H., Yang, J., Yu, Z., Huang, P., Yang, H., Zheng, B., Liu, R., Li, Q., Hu, G., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.03.037 · Cited by 25
Novel approaches to targeting BRD4
Kharenko, O. A., & Hansen, H. C. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.10.003 · Cited by 22
BET Proteins: An Approach to Future Therapies in Transplantation
Suárez-Álvarez, B., Rodríguez, R. M. A., Ruiz‐Ortega, M., & López‐Larrea, C. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14221 · Cited by 19
Li, J., Zou, W., Yu, K., Liu, B., Liang, W., Wang, L., Lu, Y., Jiang, Z., Wang, A., & Zhu, J. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1906663 · Cited by 19
Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors
Li, J., Wang, P., Zhou, B., Shi, J., Liu, J., Li, X., Fan, L., Zheng, Y., & Ouyang, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.057 · Cited by 16
Self-citationBromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature
Jiménez, I., Baruchel, A., Doz, F., & Schulte, J. H. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26334 · Cited by 16
Chen, P., Yang, Y., Yang, L., Tian, J., Zhang, F., Zhou, J., & Zhang, H. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.034 · Cited by 16
Fragment‐Based Drug Discovery in the Bromodomain and Extra‐Terminal Domain Family
Radwan, M., & Serya, R. A. T. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700147 · Cited by 13
Zhi, Y., Wang, S., Huang, W., Zeng, S., Liang, M., Zhang, C., Ma, Z., Wang, Z., Zhang, Z., & Shen, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.067 · Cited by 9
Yang, Y., Chen, P., Zhao, L., Zhang, F., Zhang, H., & Zhou, J. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00474 · Cited by 9
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundSelf-citationEpigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications
Ma, C., Cheng, J., Gu, J. H., & Wang, Q. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00373-5 · Cited by 66
Targeting bromodomain-containing proteins: research advances of drug discovery
Pan, Z., Zhao, Y., Wang, X., Xie, X., Liu, M., Zhang, K., Wang, L., Bai, D., Foster, L. J., Shu, R., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00127-1 · Cited by 44
Jiang, W., Hou, Q., Xu, H., Yang, K., Wang, X., Zhang, K., Zeng, Y., Li, W., Wang, B., Luo, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02104 · Cited by 34
An updated patent review of BRD4 degraders
Ma, Z., Zhang, C., Bolinger, A. A., & Zhou, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400166 · Cited by 35
Metadata
- Authors
- Chen, J., Tang, P., Wang, Y., Wang, J., Yang, C., Li, Y., Yang, G., Wu, F., Zhang, J., & Ouyang, L.
- Affiliations
- Sichuan University (CN)
- University of Tennessee Health Science Center (US)
- Corresponding author
- Zhang, Jifa
- Ouyang, Liang
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-03-24
- Volume
- 65
- Issue
- 7
- Pages
- 5184-5211
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4220998638
- Cited by
- 62
- References
- 117
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 18 · 2023: 13 · 2022: 4
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
- China Postdoctoral Science Foundation (2020M673268)
- Department of Science and Technology of Sichuan Province (2019YFS0003)
- National Natural Science Foundation of China (81874290, 81903502, 81922064, 82073318)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- BET proteins, bromodomain inhibitors, selective inhibitors, histone acetylation, drug selectivity, drug toxicity, cancer therapy, inflammatory diseases, small molecule inhibitors
- MeSH terms
- Protein Domains, Histones, Humans, Neoplasms, Prospective Studies, Transcription Factors, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.